Faller DV - Search Results

1

Advances in Virus-Directed Therapeutics against Epstein-Barr Virus-Associated Malignancies.

Ghosh SK, Perrine SP, Faller DV. Ghosh SK, et al. Among authors: faller dv. Adv Virol. 2012;2012:509296. doi: 10.1155/2012/509296. Epub 2012 Mar 5. Adv Virol. 2012. PMID: 22500168 Free PMC article.

2

A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies.

Perrine SP, Hermine O, Small T, Suarez F, O'Reilly R, Boulad F, Fingeroth J, Askin M, Levy A, Mentzer SJ, Di Nicola M, Gianni AM, Klein C, Horwitz S, Faller DV. Perrine SP, et al. Among authors: faller dv. Blood. 2007 Mar 15;109(6):2571-8. doi: 10.1182/blood-2006-01-024703. Epub 2006 Nov 21. Blood. 2007. PMID: 17119113 Free PMC article. Clinical Trial.

3

Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies.

Faller DV, Mentzer SJ, Perrine SP. Faller DV, et al. Curr Opin Oncol. 2001 Sep;13(5):360-7. doi: 10.1097/00001622-200109000-00008. Curr Opin Oncol. 2001. PMID: 11555713 Review.

4

Short, discontinuous exposure to butyrate effectively sensitizes latently EBV-infected lymphoma cells to nucleoside analogue antiviral agents.

Ghosh SK, Forman LW, Akinsheye I, Perrine SP, Faller DV. Ghosh SK, et al. Among authors: faller dv. Blood Cells Mol Dis. 2007 Jan-Feb;38(1):57-65. doi: 10.1016/j.bcmd.2006.10.008. Epub 2006 Dec 11. Blood Cells Mol Dis. 2007. PMID: 17161633 Free PMC article.

5

Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents.

Ghosh SK, Perrine SP, Williams RM, Faller DV. Ghosh SK, et al. Among authors: faller dv. Blood. 2012 Jan 26;119(4):1008-17. doi: 10.1182/blood-2011-06-362434. Epub 2011 Dec 7. Blood. 2012. PMID: 22160379 Free PMC article.

6

Butyrate histone deacetylase inhibitors.

Steliou K, Boosalis MS, Perrine SP, Sangerman J, Faller DV. Steliou K, et al. Among authors: faller dv. Biores Open Access. 2012 Aug;1(4):192-8. doi: 10.1089/biores.2012.0223. Biores Open Access. 2012. PMID: 23514803 Free PMC article.

7

Leukemia virus long terminal repeat activates NFkappaB pathway by a TLR3-dependent mechanism.

Abujamra AL, Spanjaard RA, Akinsheye I, Zhao X, Faller DV, Ghosh SK. Abujamra AL, et al. Among authors: faller dv. Virology. 2006 Feb 20;345(2):390-403. doi: 10.1016/j.virol.2005.10.003. Epub 2005 Nov 14. Virology. 2006. PMID: 16289658 Free PMC article.

8

Mutations that abrogate transactivational activity of the feline leukemia virus long terminal repeat do not affect virus replication.

Abujamra AL, Faller DV, Ghosh SK. Abujamra AL, et al. Among authors: faller dv. Virology. 2003 May 10;309(2):294-305. doi: 10.1016/s0042-6822(03)00069-2. Virology. 2003. PMID: 12758176 Free article.

9

Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma.

Mentzer SJ, Fingeroth J, Reilly JJ, Perrine SP, Faller DV. Mentzer SJ, et al. Among authors: faller dv. Blood Cells Mol Dis. 1998 Jun;24(2):114-23. doi: 10.1006/bcmd.1998.0178. Blood Cells Mol Dis. 1998. PMID: 9628848 Free article.

10

Feline leukemia virus long terminal repeat activates collagenase IV gene expression through AP-1.

Ghosh SK, Faller DV. Ghosh SK, et al. Among authors: faller dv. J Virol. 1999 Jun;73(6):4931-40. doi: 10.1128/JVI.73.6.4931-4940.1999. J Virol. 1999. PMID: 10233955 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

271 results

Search Page

Filters